Last reviewed · How we verify
Nausidol — Competitive Intelligence Brief
marketed
pipamazine
5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Nausidol (PIPAMAZINE).
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Nausidol TARGET | PIPAMAZINE | marketed | pipamazine | 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A | ||
| DIBENZEPIN | DIBENZEPIN | marketed | dibenzepin | 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (pipamazine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Nausidol CI watch — RSS
- Nausidol CI watch — Atom
- Nausidol CI watch — JSON
- Nausidol alone — RSS
- Whole pipamazine class — RSS
Cite this brief
Drug Landscape (2026). Nausidol — Competitive Intelligence Brief. https://druglandscape.com/ci/pipamazine. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab